Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Revive Therapeutics Ltd
(OP:
RVVTF
)
0.0130
-0.0010 (-7.14%)
Delayed Quote
Updated: 12:57 PM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Revive Therapeutics Ltd
< Previous
1
2
3
Next >
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
September 15, 2026
Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs
From
Revive Therapeutics Ltd.
Via
ACCESS Newswire
Revive Therapeutics Announces Proposed Shares for Debt Settlement
August 19, 2026
From
Revive Therapeutics Ltd.
Via
ACCESS Newswire
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
August 19, 2026
From
Revive Therapeutics Ltd.
Via
ACCESS Newswire
Revive Therapeutics Reports Grant of Options
August 14, 2026
From
Revive Therapeutics Ltd.
Via
ACCESS Newswire
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
May 20, 2026
Via
ACCESS Newswire
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
March 11, 2026
Via
ACCESS Newswire
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
December 15, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
November 21, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
September 19, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Extension of Proposed Private Placement
September 05, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
August 11, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
July 30, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
July 08, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
June 26, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Advances with Next-Generation Bucillamine Development
June 04, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
May 12, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Proposed Shares for Debt Transaction
April 21, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
April 10, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
April 01, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Results of Annual Shareholder Meeting
March 19, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis
March 03, 2025
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading...
Via
Newsfile
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
March 03, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
February 03, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
January 08, 2025
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
November 12, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
October 31, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
September 18, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
August 28, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
July 02, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
June 12, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
